Johnson & Johnson Trading Volume Surges 31.67% to 42nd Rank as Stock Price Rises 2.87%

On April 3, 2025, Johnson & Johnson (JNJ) saw a significant increase in trading volume, with a total of 21.13 billion shares traded, marking a 31.67% rise from the previous day. This surge placed JNJ at the 42nd position in terms of trading volume for the day. The stock price of JNJ also rose by 2.87%, marking the second consecutive day of gains, with a total increase of 4.29% over the past two days.

Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, Inc., integrating the company as a business unit within its Innovative Medicine division. This strategic move is expected to bolster Johnson & Johnson's neuroscience portfolio, particularly with the addition of CAPLYTA® (lumateperone), a treatment for bipolar I and II disorders.

The acquisition of Intra-Cellular Therapies is a significant step for Johnson & Johnson, as it aims to solidify its leadership in the neuroscience field. The addition of CAPLYTA® to its portfolio is expected to enhance the company's capabilities in developing innovative treatments for mental health conditions.